Substitute for form 1449A/PTO INFORMATION DISCLOSURE OIPE STATEMENT BY APPLICANT							
	(use as many she	SEP 2					
Sheet	1	of	3				

	Fatelit and Tradeliank Office; 0:3 DEFAR IMENT OF COMMERCE	3			
COMPLETE IF KNOWN					
Application Number	10/523,286				
Filing Date	February 3, 2005				
First Named Inventor	Christopher J. Dinsmore				
Group Art Unit	To Be Assigned				
Examiner Name	To Be Assigned				
Attorney Docket Number	21007YP				

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)		Date of Publication of Cited Document MM-DD-YYYY		
	1	US 5,527,819		Williams, et al.	06/18/1996		
			-				
			<u> </u>				
			_				
			-				
			-				
			-				
			+	•			
			-				
		l	ŀ				

			FORE	IGN PATENT D	OCUMENTS	
			Foreign Patent Docume	nt		Date of Publication of
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
·						
Examine Signatur	er re				Date Considered	

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449B/PTO				COMPLETE IF KNOWN			
		Application Number	10/523,286				
c	TATEMENT DV	ΑT	DI ICANT 43	Filing Date	February 3, 2005		
3	STATEMENT BY APPLICANT SEP 2 6 2006		First Named Inventor	Christopher J. Dinsmore			
			\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Group Art Unit	To Be Assigned		
	(use as many sheets	as r	nessusary)	Examiner Name	To Be Assigned		
Sheet	1	of	2		21007YP		

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
	1	Arteaga, C. L. et al., "Blockade of the Type 1 Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice", J. Clin. Invest, Vol. 84, pp. 1418-1423 (1989)					
	2	Baserga, R., "Controlling IGF-receptor function: a possible strategy for tumor therapy", Trends in Biotechnology (TIBTECH), Vol. 14, pp. 150-152 (1996)					
	3	Baserga, R., "Oncogenes and the Strategy of Growth Factors", Cell, Vol. 79, pp. 927-930 (1994)					
	4	Baserga, R., "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?", Cancer Research, Vol. 55, pp. 249-252 (1995)					
	5	Bolen J. B. et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction", The FASEB Journal, Vol. 6, pp. 3403-3409 (1992)					
	6	Cance W. G., et al., "NOVEL PROTEIN KINASES EXPRESSED IN HUMAN BREAST CANCER", Int. J. Cancer, Vol. 54, pp. 571-577 (1993)					
	7	Coppola, D., et al., "A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor", MOLECULAR AND CELLULAR BIOLOGY, Vol. 14, pp. 4588-4595 (1994)					
	8	Goldring, M. B., et al., "Cytokines and Cell Growth Control", Eukaryotic Gene Expression, Vol. 1, pp. 301-326 (1991)					
	9	Kenyon, C., et al., "A Conserved Regulatory System for Aging", Cell, Vol. 105, pp. 165-168 (2001)					
	10	Khandwala, H. M., et al., "The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth", Endocrine Reviews, Vol. 21, pp. 215-244 (2000)					
	11	Kimura, K. D., et al., "daf-2, an Insulin Receptor-Like Gene That Regulates Longevity and Diapause in Caenorhabditis elegans", SCIENCE, Vol. 277, pp. 942-946 (1997)					
	12	Macaulay, V. M., et al., "Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells", Cancer Research, Vol. 50, pp. 2511-2517 (1990)					
	13	Minet et al., "Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis (Review)", International Journal of Molecular Medicine, Vol. 5, pp. 253-259 (2000)					
	14	Plowman, G. E., et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention", DN&P, Vol. 7, pp. 334-339 (1994)					
	15	Sandberg-Nordqvist, A. C., et al., "Characterization of Insulin-like Growth Factor 1 in Human Primary Brain Tumors", Cancer Research, Vol. 53, pp. 2475-2478 (1993)					

	 <del></del>	
Examiner	Date	1
Signature	Considered	
Signature	Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

					THE THE PROPERTY OF THE PROPERTY OF COMMERCE	
Si	ubstitute for form 1449B/PTO			COMPLETE IF KNOWN		
I	NFORMATION 1	DIS	CLOSURE	Application Number	10/523,286	
C	OD A ODERNIENIO DSZ	A TO	DI ICANIT	Filing Date	February 3, 2005	
3	TATEMENT BY	AP	PLICANI	First Named Inventor	Christopher J. Dinsmore	
			,	Group Art Unit	To Be Assigned	
	(use as many sheets	as n	ecessary)	Examiner Name	To Be Assigned	
Sheet	2	of	2	Attorney Docket Number	21007YP	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
	16	Scalia, P., et al., "Regulation of the Akt/Glycogen Synthase Kinase-3 Axis by Insulin-Like Growth Factor-II Via Activation of the Human Insulin Receptor Isoform -A", Journal of Cellular Biochemistry, Vol. 82, pp. 610-618 (2001)					
	17	Sepp-Lorenzino, L., et al., "HERBIMYCIN A INHIBITS THE IGF-I RECEPTOR PROTEIN TYROSINE KINASE AND CELLULAR PROLIFERATION IN HUMAN BREAST CANCER CELLS", J. Cell Biochem. Suppl., Vol. 18b, pp. 246 (1994)					
	18	Smith, L. E., et al., "Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor", Nature Medicine, Vol. 5, pp. 1390-1395 (1999)					
	19	Strauss, E., "LONGEVITY: Growing Old Together", Science, Vol. 292, pp. 41-43 (2001)					
	20	Tatar, M. et al., "A Mutant Drosophila Insulin Receptor Homolog that Extends Life-Span and Impairs Neuroendocrine Function", SCIENCE, Vol. 292, pp. 107-110 (2001)					
	21	Zhang, L., et al., "Gene Expression Profiles in Normal and Cancer Cells", SCIENCE, Vol. 276, pp. 1268-1272 (1997)					

Examiner	Date Considered	
Signature	Considered	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.